Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase 2/3 1Phase 1 1

Status

Recruiting 4Completed 4Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Lymphoid 1

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 282Prostatic Neoplasms 160Colorectal Neoplasms 155Carcinoma, Hepatocellular 144Neoplasms 134Leukemia, Myeloid, Acute 132Lung Neoplasms 115Squamous Cell Carcinoma of Head and Neck 108Triple Negative Breast Neoplasms 102Multiple Myeloma 102Recurrence 99Pancreatic Neoplasms 94Stomach Neoplasms 93Ovarian Neoplasms 87Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Precursor Cell Lymphoblastic Leukemia-Lymphoma 68Esophageal Neoplasms 67Uterine Cervical Neoplasms 66Melanoma 65Brain Neoplasms 65Rectal Neoplasms 62Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 57Lymphoma 55Myelodysplastic Syndromes 54Esophageal Squamous Cell Carcinoma 54

Interventions

tocilizumab 1talquetamab 1siltuximab 1obinutuzumab 1glofitamab 1Oxaliplatin 1Gemcitabine 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Cytokine Release Syndrome × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06421675 2026-04-27

EMBRACE

Ontario Clinical Oncology Group (OCOG)

Phase 2 Recruiting
40 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
20 enrolled
Plasma cell

Cytokine Release Syndrome, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡